Redswell Global Launches Clinical Trials: Thousands of New Crown Patients Will Be Enrolled

The potentially effective drug Rhedcieve, a potentially effective drug for new coronary pneumonia, will begin clinical trials worldwide. On February 26, local time, Gilead Sciences (Nasdaq: GILD) announced on its website that it had launched two Phase III clinical studies to assess the safety and efficacy of remdesivir in treating adult cases infected with the new coronavirus.

(Original title: Redsiewe launches two Phase III clinical trials worldwide: thousands of new coronapatients will be enrolled)

Journalist, Bao Yu

Redswell Global Launches Clinical Trials: Thousands of New Crown Patients Will Be Enrolled

Starting in March this year, these randomized, open, multi-center studies will be conducted in medical institutions, mainly in Asia and other countries with high number of confirmed cases around the world, with a population of about 1,000 patients. The study will assess the effects of Redcivir during the injection time of both drugs. The main endpoint of the two studies was clinical improvement.

One study randomly selected about 400 patients with severe clinical performance of COVID-19 to be randomly assigned on a 1:1 scale and subjected to Redciewe treatment for 5 or 10 days. On the first day of intravenous lybeth, 200 mg of ridsievir is administered daily until the 5th or 10th day, in addition to standard medical care. The main purpose of this study was to assess the effects of Redciewe by measuring the normalization of fever and oxygen saturation (T?lt; 36.6 C armpits, 37.2 C oral cavities, slt; 37.8 C rectum; and Sp02 and 94% for at least 24 hours until the 14th day).

The second study randomly selected about 600 patients with moderate clinical symptoms and received only 5 or 10 days of ridsiewere or standard treatment. About 600 participants will also be randomly assigned on a 1:1 scale, receiving 200 mg of ridsieweon on the first day, and then receiving 100 mg of Ridsiewe in addition to the daily standard of treatment until the fifth or 10th day. The main purpose of this study was to measure the difference in the effectiveness of standard treatment with the treatment of Rhedcives, based on the proportion of patients discharged on the 14th day.

Before the studies began, the U.S. Food and Drug Administration (FDA) quickly reviewed and accepted Gilead’s application for a new drug study (IND) for new coronary pneumonia.

The new clinical study also includes two clinical trials already led by the China-Japan Friendship Hospital in Hubei, China, and, more recently, a clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States. The trial, led by the University of Nebraska Medical Center and the U.S. National Institute of Allergy and Infectious Diseases, will be conducted in as many as 50 locations around the world, according to cNBC. Gilead has donated drugs to the research institutions and provided scientific support for the research, which is expected to be published in April.

“Gilead’s primary focus is to quickly identify the safety and efficacy of Redciwe as a potential treatment for new coronary pneumonia (COVID-19), and this series of complementary studies will help us to obtain a wider range of data in a short period of time on a global scale.” “Gilead Science’s chief medical officer, Merdad Parsey, said.

He also noted that the pace at which Redciwe enters the clinical development of new coronaviruses reflects the urgent need for treatment options and the joint commitment of industry, governments, global health organizations and health care providers to address this public health threat in the most urgent way.

Ridsiewe is a drug that has not been licensed or approved anywhere in the world and has not been shown to be safe and effective. Gilead is working with government agencies, non-governmental organizations and local regulatory authorities to provide Redciewe to eligible new coronavirus users and to treat patients with sympathetic medication in addition to ongoing clinical studies.

Redciwe is a nucleotide analogue being studied, with broad-spectrum antiviral activity, in vitro and in vivo animal models to fight a variety of emerging viral pathogens, including Ebola virus, Marburg virus, MERS and SARS virus. Gilead has previously conducted studies of the drug for healthy volunteers and people infected with the Ebola virus. The company stressed that individual cases of sympathetic drug use are not sufficient to determine the safety and efficacy of Redciewe’s treatment of the new coronavirus, which can only be determined by prospective clinical trials.

“We think there’s only one drug that might have a real effect, and that’s Ridsie, ” Bruce Aylward, assistant director-general of the World Health Organization,” said CNN reported. “